- Conditions
- Breast Cancer
- Interventions
- bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, adjuvant therapy, immunoscintigraphy
- Biological · Drug · Other + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colorectal Neoplasms, Colorectal Cancer, Colorectal Tumor, COlorectal Carcinoma
- Interventions
- Iodine-124 labeled humanized A33 (antibody)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- pharmacological study, single photon emission computed tomography, iodine I 123 anti-CEA recombinant diabody T84.66
- Other · Procedure · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Primary Amyloidosis
- Interventions
- 124I-labeled monoclonal antibody Mu 11-1F4
- Biological
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Colorectal Cancer
- Interventions
- cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
- Dietary Supplement · Genetic · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Lymphoma
- Interventions
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Procedure · Radiation
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Cuyahoga Falls, Ohio + 1 more
- Conditions
- Colorectal Neoplasm
- Interventions
- 2-Fluoro-2-deoxyglucose
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- AL Amyloidosis
- Interventions
- Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
- Biological
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- AL Amyloidosis
- Interventions
- 124I-labeled monoclonal antibody Mu 11-1F4
- Biological
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Anemia, Metastatic Cancer, Myelodysplastic Syndromes, Precancerous Condition, Prostate Cancer
- Interventions
- fluorescence in situ hybridization, microarray analysis, molecular diagnostic method, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, immunoscintigraphy
- Genetic · Other · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Lymphoma
- Interventions
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Procedure · Radiation
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 120 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Clearwater, Florida • Baltimore, Maryland + 1 more